The ANVISA alert says that at the authorization and based on the data you have at this time, and launches some recommendations: a dose for children between 5 and 11 years old and 1/3 of the formula that has been approved in Brazil; a pediatric formulation is different from that approved for the public over 12 years of age, therefore, it cannot be used as a diluted adult formulation; The child to complete 12 years between the first and the second dose must be pediatric.
After ANVISA’s approval, the Minister of Health, Marcelo Queiroga, announced on Saturday, 18, that there will be a public hearing on January 4 on the vaccination of childrens in Brazil.
As reported by Queiroga, the objective of the hearing is to discuss or that is offered in public consultation, in addition to the position of the Cetai (Covid-19 Technical Advisory Board on Immunization). A discussion will serve as the basis for the final decision of the Ministry of Health. The questions that need to be analyzed are not in the technical area and not in the area of ??the Ministry of Health, in order to be followed by states and municipalities.
For 20 years, Biotecno has been inserted in this context by providing, also to the public health system, scientific chambers for the correct storage of vaccines. From adequate conservation, vaccines preserve their properties and effectively immunize the population. The ideal temperature range recommended by the manufacturer, and according to the ANVISA Cold Chain Manual, varies between 2ºC and 8ºC.
